MX2023001567A - Metodos de preparacion de nanoparticulas lipidicas. - Google Patents
Metodos de preparacion de nanoparticulas lipidicas.Info
- Publication number
- MX2023001567A MX2023001567A MX2023001567A MX2023001567A MX2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A MX 2023001567 A MX2023001567 A MX 2023001567A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- lipid nanoparticles
- preparing lipid
- lnp
- formulations
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5192—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1277—Preparation processes; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Manufacturing Of Micro-Capsules (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062369P | 2020-08-06 | 2020-08-06 | |
| US202163143703P | 2021-01-29 | 2021-01-29 | |
| US202163226395P | 2021-07-28 | 2021-07-28 | |
| PCT/US2021/044928 WO2022032087A1 (en) | 2020-08-06 | 2021-08-06 | Methods of preparing lipid nanoparticles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001567A true MX2023001567A (es) | 2023-06-28 |
Family
ID=77519867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001567A MX2023001567A (es) | 2020-08-06 | 2021-08-06 | Metodos de preparacion de nanoparticulas lipidicas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230277457A1 (https=) |
| EP (1) | EP4192432A1 (https=) |
| JP (1) | JP2023543963A (https=) |
| KR (1) | KR20230167008A (https=) |
| AU (1) | AU2021322310A1 (https=) |
| BR (1) | BR112023002071A2 (https=) |
| CA (1) | CA3190790A1 (https=) |
| IL (1) | IL300404A (https=) |
| MX (1) | MX2023001567A (https=) |
| TW (1) | TW202220637A (https=) |
| WO (1) | WO2022032087A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| CZ310613B6 (cs) | 2020-09-23 | 2026-01-28 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Lipidoidy pro transfekci nukleových kyselin a jejich použití |
| CZ310443B6 (cs) | 2021-07-19 | 2025-06-25 | Ústav organické chemie a biochemie AV ČR, v. v. i. | Cyklohexanové lipidoidy pro transfekci nukleových kyselin a jejich použití |
| WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| EP4561547A1 (en) | 2022-07-29 | 2025-06-04 | ModernaTX, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| AU2023406273A1 (en) * | 2022-12-01 | 2025-05-29 | Generation Bio Co. | Synthetic single stranded nucleic acid compositions and methods thereof |
| WO2024160826A1 (en) | 2023-01-31 | 2024-08-08 | BioNTech SE | Compositions and methods |
| CN115844833A (zh) * | 2023-02-14 | 2023-03-28 | 武汉载元生物科技有限公司 | 一种可电离脂质纳米粒及其制备方法 |
| WO2024197309A1 (en) | 2023-03-23 | 2024-09-26 | Modernatx, Inc. | Peg targeting compounds for delivery of therapeutics |
| EP4683665A1 (en) | 2023-03-23 | 2026-01-28 | ModernaTX, Inc. | Peg targeting compounds for delivery of therapeutics |
| WO2024197310A1 (en) | 2023-03-23 | 2024-09-26 | Modernatx, Inc. | Peg targeting compounds for delivery of therapeutics |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
| WO2025244134A1 (en) * | 2024-05-24 | 2025-11-27 | Fujifilm Corporation | Method to deliver a payload to cells, and lipid composition |
| WO2025261607A1 (en) | 2024-06-21 | 2025-12-26 | BioNTech SE | Particles, compositions and methods |
| WO2026027695A1 (en) | 2024-08-01 | 2026-02-05 | BioNTech SE | Compositions and methods |
| WO2026039780A1 (en) * | 2024-08-16 | 2026-02-19 | Modernatx, Inc. | Stable lipid nanoparticle compositions prepared without polymeric lipids and uses thereof |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2390331B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| US7745651B2 (en) * | 2004-06-07 | 2010-06-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
| EP2487258B1 (en) | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer |
| JP5490413B2 (ja) | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| ES2448491T3 (es) | 2006-03-02 | 2014-03-14 | The Ohio State University Research Foundation | Perfil de expresión de microARN asociado con cáncer de páncreas |
| WO2008036765A2 (en) | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| WO2008073915A2 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| US8415096B2 (en) | 2007-05-23 | 2013-04-09 | University Of South Florida | Micro-RNAs modulating immunity and inflammation |
| WO2008154098A2 (en) | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| JP2011505143A (ja) | 2007-11-30 | 2011-02-24 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | マイクロｒｎａ発現プロファイリング及び肺癌における末梢血ターゲティング |
| US20090263803A1 (en) | 2008-02-08 | 2009-10-22 | Sylvie Beaudenon | Mirnas differentially expressed in lymph nodes from cancer patients |
| AU2009219193A1 (en) | 2008-02-28 | 2009-09-03 | The Ohio State University Research Foundation | MicroRNA signatures associated with human chronic lymphocytic leukemia (CCL) and uses thereof |
| EP2112235A1 (en) | 2008-04-24 | 2009-10-28 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Compositions and methods for microRNA expression profiling of nasopharyngeal carcinoma |
| WO2010018563A2 (en) | 2008-08-12 | 2010-02-18 | Rosetta Genomics Ltd. | Compositions and methods for the prognosis of lymphoma |
| CN104119242B (zh) * | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
| WO2010055487A2 (en) | 2008-11-13 | 2010-05-20 | Koninklijke Philips Electronics N.V. | Compositions and methods for micro-rna expession profiling of colorectal cancer |
| EP2358902A1 (en) | 2008-12-10 | 2011-08-24 | Universität Regensburg | Compositions and methods for micro-rna expression profiling of cancer stem cells |
| US20120264626A1 (en) | 2009-05-08 | 2012-10-18 | The Ohio State University Research Foundation | MicroRNA Expression Profiling and Targeting in Chronic Obstructive Pulmonary Disease (COPD) Lung Tissue and Methods of Use Thereof |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| WO2011076142A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expession profiling in plasma of colorectal cancer |
| WO2011076143A1 (en) | 2009-12-24 | 2011-06-30 | Fudan University | Compositions and methods for microrna expression profiling of lung cancer |
| EP2341145A1 (en) | 2009-12-30 | 2011-07-06 | febit holding GmbH | miRNA fingerprint in the diagnosis of diseases |
| WO2011094683A2 (en) | 2010-01-29 | 2011-08-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Method of identifying myelodysplastic syndromes |
| EP2354246A1 (en) | 2010-02-05 | 2011-08-10 | febit holding GmbH | miRNA in the diagnosis of ovarian cancer |
| US20130059015A1 (en) | 2010-03-11 | 2013-03-07 | H. Lee Moffitt Cancer Center & Research Institute | Human Cancer micro-RNA Expression Profiles Predictive of Chemo-Response |
| WO2011157294A1 (en) | 2010-06-16 | 2011-12-22 | Universita' Degli Studi Di Padova | Compositions for use in treating or preventing cancer, breast cancer, lung cancer, ovarian cancer, metastasis, heart failure, cardiac remodelling, dilated cardiomyopathy, autoimmune diseases, or diseases or disorders related thereto |
| EP2603231B1 (en) * | 2010-07-13 | 2021-12-29 | Rhode Island Board Of Governors For Higher Education | Compositions comprising a pH-sensitive membrane insertion polipeptide. |
| WO2012151212A1 (en) | 2011-05-01 | 2012-11-08 | University Of Rochester | Multifocal hepatocellular carcinoma microrna expression patterns and uses thereof |
| WO2012153187A2 (en) | 2011-05-06 | 2012-11-15 | Xentech | Markers for cancer prognosis and therapy and methods of use |
| CN107043334B (zh) * | 2011-06-08 | 2020-06-16 | 日东电工株式会社 | 用于定向药物输送和增强siRNA活性的化合物 |
| JP5965481B2 (ja) | 2011-07-15 | 2016-08-03 | レオ ファーマ アクティーゼルスカブ | 皮膚ｔ細胞リンパ腫（ｃｔｃｌ）の診断用マイクロｒｎａプロファイリング |
| EP2751292A4 (en) | 2011-09-01 | 2015-05-20 | Allegro Diagnostics Corp | METHOD AND COMPOSITIONS FOR DETECTING CANCER BASED ON MIRNA EXPRESSION PROFILES |
| WO2013066678A1 (en) | 2011-10-26 | 2013-05-10 | Georgetown University | Microrna expression profiling of thyroid cancer |
| US20140308304A1 (en) * | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| WO2014153163A1 (en) * | 2013-03-14 | 2014-09-25 | Dicerna Pharmaceuticals, Inc. | Process for formulating an anionic agent |
| CA2906732C (en) | 2013-03-15 | 2023-08-08 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| US10821175B2 (en) * | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| EP4286012A3 (en) | 2015-09-17 | 2024-05-29 | ModernaTX, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| PL3350333T3 (pl) | 2015-09-17 | 2022-03-07 | Modernatx, Inc. | Polinukleotydy zawierające region stabilizujący ogon |
| AU2016336344A1 (en) | 2015-10-05 | 2018-04-19 | Modernatx, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| WO2017070620A2 (en) * | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| HUE057877T2 (hu) | 2015-12-22 | 2022-06-28 | Modernatx Inc | Vegyületek és készítmények terápiás szerek intracelluláris bejuttatására |
| WO2018089801A1 (en) * | 2016-11-10 | 2018-05-17 | Translate Bio, Inc. | Improved process of preparing mrna-loaded lipid nanoparticles |
| US11969506B2 (en) | 2017-03-15 | 2024-04-30 | Modernatx, Inc. | Lipid nanoparticle formulation |
| SMT202300097T1 (it) | 2017-03-15 | 2023-05-12 | Modernatx Inc | Composto e composizioni per il rilascio intracellulare di agenti terapeutici |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2019046809A1 (en) * | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| EP3813798A1 (en) * | 2018-06-28 | 2021-05-05 | AstraZeneca AB | Exosome extracellular vesicles and methods of use |
| KR20210091120A (ko) * | 2018-08-29 | 2021-07-21 | 트랜슬레이트 바이오 인코포레이티드 | Mrna-로딩된 지질 나노입자를 제조하는 개선된 공정 |
| US12263248B2 (en) | 2018-09-19 | 2025-04-01 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| CN113166783B (zh) * | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| JP7635131B2 (ja) * | 2019-01-31 | 2025-02-25 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の調製方法 |
| US20230285297A1 (en) * | 2020-01-31 | 2023-09-14 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
-
2021
- 2021-08-06 KR KR1020237007662A patent/KR20230167008A/ko not_active Withdrawn
- 2021-08-06 WO PCT/US2021/044928 patent/WO2022032087A1/en not_active Ceased
- 2021-08-06 TW TW110129190A patent/TW202220637A/zh unknown
- 2021-08-06 BR BR112023002071A patent/BR112023002071A2/pt not_active Application Discontinuation
- 2021-08-06 EP EP21762299.2A patent/EP4192432A1/en active Pending
- 2021-08-06 MX MX2023001567A patent/MX2023001567A/es unknown
- 2021-08-06 JP JP2023508048A patent/JP2023543963A/ja active Pending
- 2021-08-06 AU AU2021322310A patent/AU2021322310A1/en not_active Abandoned
- 2021-08-06 IL IL300404A patent/IL300404A/en unknown
- 2021-08-06 CA CA3190790A patent/CA3190790A1/en active Pending
- 2021-08-06 US US18/040,745 patent/US20230277457A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL300404A (en) | 2023-04-01 |
| KR20230167008A (ko) | 2023-12-07 |
| AU2021322310A1 (en) | 2023-04-13 |
| TW202220637A (zh) | 2022-06-01 |
| BR112023002071A2 (pt) | 2023-05-02 |
| JP2023543963A (ja) | 2023-10-19 |
| WO2022032087A1 (en) | 2022-02-10 |
| EP4192432A1 (en) | 2023-06-14 |
| CA3190790A1 (en) | 2022-02-10 |
| US20230277457A1 (en) | 2023-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022009410A (es) | Metodos de preparacion de nanoparticulas lipidicas. | |
| MX2023001567A (es) | Metodos de preparacion de nanoparticulas lipidicas. | |
| EP4427739A3 (en) | Methods of preparing lipid nanoparticles | |
| Zheng et al. | Ultrasound-augmented mitochondrial calcium ion overload by calcium nanomodulator to induce immunogenic cell death | |
| WO2022066898A3 (en) | Methods of producing extracellular vesicles | |
| MX2021011242A (es) | Conjugados de vesícula extracelular y usos de estos. | |
| PH12022550112A1 (en) | A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersomes | |
| MX2022001770A (es) | Vesícula extracelular unida a moléculas y usos de esta. | |
| SG10201908354VA (en) | Riluzole prodrugs and their use | |
| MX2020002348A (es) | Métodos de elaboración de nanopartículas lipídicas. | |
| EP4306524A3 (en) | Lymphatic system-directing lipid prodrugs | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| EP3741362A3 (en) | Surface-modified mesoporous silica nanoparticle for blood-brain barrier penetration, tumor targeting and cancer metastasis treatment, methods of production and uses thereof | |
| TW200637614A (en) | Bendamustine pharmaceutical compositions | |
| Ouyang et al. | Metronomic doses of temozolomide enhance the efficacy of carbon nanotube CpG immunotherapy in an invasive glioma model | |
| MX354702B (es) | Metodo de produccion de niveles fisiologicos y terapeuticos de oxido nitrico por medio de un sistema de suministro oral. | |
| GB0814302D0 (en) | Compounds and methods | |
| EP4272551A3 (en) | Differentiation and use of human microglia-like cells from pluripotent stem cells and hematopoietic progenitors | |
| MX2022012671A (es) | Vacuna terapeutica individualizada contra el cancer. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| WO2023104114A3 (en) | Rna formulations and lipids | |
| WO2022119883A3 (en) | Lipid nanoparticle compositions containing monoester cationic lipids | |
| WO2023028165A3 (en) | Tumor-associated calcium signal transducer 2 (tacstd2) antibody-maytansine conjugates and methods of use thereof | |
| AR123171A1 (es) | Métodos para preparar nanopartículas lipídicas | |
| MX2024012319A (es) | Conjugado anticuerpo-fármaco que comprende anticuerpo contra transductor de señal de calcio asociado a tumor 2 (trop2) humano y uso de este |